My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,025.00 -19.67 (-1.88%)

Official Closing Price Updated: 7:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗

February 03, 2026

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.

Via The Motley Fool

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

Via The Motley Fool

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

February 03, 2026

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

Via Barchart.com

Veteran Biopharma Engineer Ge Yang Attracts Investor Interest with Vision to Redefine Global Pharma Manufacturing

February 03, 2026

Via AB Newswire

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

Via Stocktwits

Eli Lilly & Co (NYSE:LLY) Emerges as a Top GARP Investment Candidate ↗

January 30, 2026

Via Chartmill

If You Invested $100 In Eli Lilly and Co Stock 5 Years Ago, You Would Have This Much Today ↗

February 03, 2026

Via Benzinga

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

February 03, 2026

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Via Barchart.com

Topics ETFs

Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits ↗

February 03, 2026

Eli Lilly (LLY) Q4 Preview: Analysts predict a $17.9B revenue beat, but rising R&D costs could challenge the $6.96 EPS target.

Via Benzinga

Eli Lilly (LLY) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 02, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Wednesday before market hours. Here’s what to expect.

Via StockStory

Google Stock Hits Record High, Leads Select Group Of 14 Stocks Onto Best Stock lists ↗

February 02, 2026

Search and AI data center king Google closed at 343.69 Monday. It was up 1.7% for the day and popped to a record close.

Via Investor's Business Daily

Topics Artificial Intelligence

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Via TokenRing AI

Topics Artificial Intelligence

Is Novo Nordisk Stock a Bargain Right Now? ↗

February 02, 2026

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

Via The Motley Fool

VenHub Appoints Former Amazon Executive, Ian Rasmussen, to Spearhead Nationwide Smart Store Expansion with Focus on Strategic Partnerships and Enterprise Integrations

February 02, 2026

VenHub Global, Inc. (NASDAQ:VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced the appointment of Ian Rasmussen as

Via PressReach

3 Headwinds Facing Pfizer in 2026 ↗

February 02, 2026

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Via The Motley Fool

Topics Intellectual Property

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

Commodity Volatility, Earnings and Other Key Things to Watch

February 01, 2026

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

Via Barchart.com

Topics Economy

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? ↗

January 31, 2026

This could finally be the start of the drugmaker's comeback.

Via The Motley Fool

Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill ↗

January 31, 2026

Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a game-changer for the launch of its experimental weight-loss pill orforglipron, potentially expanding access to...

Via Benzinga

Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗

January 30, 2026

CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk.

Via Stocktwits

Topics Government

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗

January 30, 2026

Novo Nordisk's weight loss pill could give the company's numbers a big boost this year.

Via The Motley Fool

Stock Yards Bank Buys $25 Million of Stock Yards Bancorp Stock ↗

January 30, 2026

Stock Yards Bancorp delivers commercial banking and wealth management services across key Midwest metropolitan markets.

Via The Motley Fool

Topics Regulatory Compliance

Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases ↗

January 30, 2026

Novo Nordisk sharply increased U.S. advertising for Wegovy and Ozempic in 2025, outspending Eli Lilly as competition for obesity drugs intensified.

Via Benzinga

FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗

January 30, 2026

The target action date for orforglipron is now April 10.

Via The Motley Fool

Should You Buy Eli Lilly Before Feb. 4? ↗

January 30, 2026

Is there another beat-and-raise in the pharmaceutical giant's near future?

Via The Motley Fool

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion ↗

January 29, 2026

Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease treatments and gene therapies targeting hearing loss.

Via Benzinga

How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity ↗

January 29, 2026

Roche hopes to rival Eli Lilly and Novo Nordisk in the weight-loss space.

Via Investor's Business Daily

Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead. ↗

January 29, 2026

This pharmaceutical giant is increasingly looking unstoppable.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.